Literature DB >> 20855733

Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors.

Daniel Bertrand1, Sonia Bertrand, Estelle Neveu, Prabhavathi Fernandes.   

Abstract

Adverse effects have limited the clinical use of telithromycin. Preferential inhibition of the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (α3β2 and NMJ), the ciliary ganglion of the eye (α3β4 and α7), and the vagus nerve innervating the liver (α7) could account for the exacerbation of myasthenia gravis, the visual disturbance, and the liver failure seen with telithromycin use. The studies presented here enable the prediction of expected side effects of macrolides in development, such as solithromycin (CEM-101).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855733      PMCID: PMC2981250          DOI: 10.1128/AAC.00840-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Telithromycin and myasthenia gravis.

Authors:  Richard B Nieman; Kristen Sharma; Helen Edelberg; Steve E Caffe
Journal:  Clin Infect Dis       Date:  2003-12-01       Impact factor: 9.079

Review 2.  Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.

Authors:  John A Dani; Daniel Bertrand
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  An automated system for intracellular and intranuclear injection.

Authors:  Ron C Hogg; Florence Bandelier; Audrey Benoit; Roland Dosch; Daniel Bertrand
Journal:  J Neurosci Methods       Date:  2007-12-08       Impact factor: 2.390

4.  Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

Authors:  S Jaruratanasirikul; R Hortiwakul; T Tantisarasart; N Phuenpathom; S Tussanasunthornwong
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Telithromycin blocks neuromuscular transmission and inhibits nAChR currents in vitro.

Authors:  Chang-Ning Liu; Chris J Somps
Journal:  Toxicol Lett       Date:  2010-02-12       Impact factor: 4.372

Review 6.  Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.

Authors:  Jun Shi; Guy Montay; Vijay O Bhargava
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Immunohistochemical localization of neuronal nicotinic receptor subtypes at the pre- and postjunctional sites in mouse diaphragm muscle.

Authors:  H Tsuneki; I Kimura; K Dezaki; M Kimura; C Sala; G Fumagalli
Journal:  Neurosci Lett       Date:  1995-08-18       Impact factor: 3.046

Review 8.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

  8 in total
  19 in total

1.  Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors:  J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Antibiotic-induced neurotoxicity.

Authors:  Shamik Bhattacharyya; Ryan Darby; Aaron L Berkowitz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 4.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

5.  Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.

Authors:  Annelot C M van Esbroeck; Antonius P A Janssen; Armand B Cognetta; Daisuke Ogasawara; Guy Shpak; Mark van der Kroeg; Vasudev Kantae; Marc P Baggelaar; Femke M S de Vrij; Hui Deng; Marco Allarà; Filomena Fezza; Zhanmin Lin; Tom van der Wel; Marjolein Soethoudt; Elliot D Mock; Hans den Dulk; Ilse L Baak; Bogdan I Florea; Giel Hendriks; Luciano De Petrocellis; Herman S Overkleeft; Thomas Hankemeier; Chris I De Zeeuw; Vincenzo Di Marzo; Mauro Maccarrone; Benjamin F Cravatt; Steven A Kushner; Mario van der Stelt
Journal:  Science       Date:  2017-06-09       Impact factor: 47.728

Review 6.  Natural Products as Platforms To Overcome Antibiotic Resistance.

Authors:  Sean E Rossiter; Madison H Fletcher; William M Wuest
Journal:  Chem Rev       Date:  2017-09-27       Impact factor: 60.622

7.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 8.  Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Authors:  George G Zhanel; Erika Hartel; Heather Adam; Sheryl Zelenitsky; Michael A Zhanel; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew J Walkty; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

9.  A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.

Authors:  V Samuel Raj; Tarani Kanta Barman; Vandana Kalia; Kedar Purnapatre; Smita Dube; Ramkumar G; Pragya Bhateja; Tarun Mathur; Tridib Chaira; Dilip J Upadhyay; Yogesh B Surase; R Venkataramanan; Anjan Chakrabarti; Biswajit Das; Pradip K Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 10.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.